SG Americas Securities LLC Has $640,000 Stock Position in Revolution Medicines, Inc. (NASDAQ:RVMD)

SG Americas Securities LLC boosted its stake in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 516.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 18,103 shares of the company's stock after purchasing an additional 15,164 shares during the quarter. SG Americas Securities LLC's holdings in Revolution Medicines were worth $640,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of RVMD. IFP Advisors Inc bought a new stake in shares of Revolution Medicines in the fourth quarter valued at about $34,000. Sterling Capital Management LLC raised its holdings in Revolution Medicines by 588.7% in the 4th quarter. Sterling Capital Management LLC now owns 1,956 shares of the company's stock valued at $86,000 after acquiring an additional 1,672 shares in the last quarter. Farther Finance Advisors LLC raised its holdings in Revolution Medicines by 368.3% in the 4th quarter. Farther Finance Advisors LLC now owns 2,051 shares of the company's stock valued at $90,000 after acquiring an additional 1,613 shares in the last quarter. Kapitalo Investimentos Ltda bought a new stake in shares of Revolution Medicines in the 4th quarter worth approximately $104,000. Finally, GF Fund Management CO. LTD. bought a new stake in shares of Revolution Medicines in the 4th quarter worth approximately $154,000. 94.34% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

RVMD has been the topic of a number of research reports. Guggenheim restated a "buy" rating and set a $80.00 price objective on shares of Revolution Medicines in a research report on Wednesday. Stifel Nicolaus lowered their price target on shares of Revolution Medicines from $78.00 to $64.00 and set a "buy" rating on the stock in a report on Tuesday, April 1st. Oppenheimer increased their price objective on shares of Revolution Medicines from $70.00 to $75.00 and gave the company an "outperform" rating in a research note on Thursday, May 8th. HC Wainwright reaffirmed a "buy" rating and set a $72.00 price objective (down from $73.00) on shares of Revolution Medicines in a report on Wednesday, May 14th. Finally, Wedbush reissued an "outperform" rating and issued a $73.00 target price (up previously from $67.00) on shares of Revolution Medicines in a research note on Tuesday. Twelve research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $67.58.

Revolution Medicines Price Performance

Shares of RVMD traded down $1.62 during trading hours on Wednesday, hitting $38.41. The stock had a trading volume of 2,988,027 shares, compared to its average volume of 1,557,643. The stock has a market capitalization of $7.15 billion, a price-to-earnings ratio of -9.60 and a beta of 1.10. The company's fifty day moving average is $39.55 and its two-hundred day moving average is $40.14. Revolution Medicines, Inc. has a 52 week low of $29.17 and a 52 week high of $62.40.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($1.13) earnings per share for the quarter, missing the consensus estimate of ($1.12) by ($0.01). During the same period in the previous year, the company earned ($0.70) EPS. Equities analysts predict that Revolution Medicines, Inc. will post -3.49 EPS for the current fiscal year.

About Revolution Medicines

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.